stockrowActinium Pharmaceuticals, Inc.
ATNM Healthcare Biotechnology
Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023.
- Revenue
- +77,677.8%
- EPS
- +504.6%
- Free cash flow
- −4.91%
Quarter to June 2026, against a year earlier
Follow ATNM
Alert me
Actinium Pharmaceuticals, Inc. (ATNM) EV/Sales
As of 6 November 2026, Actinium Pharmaceuticals, Inc. (ATNM) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −95.1× (March 2026) to 238× (November 2022); the current reading is higher than 78% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −30.9× | — |
| FY2023 | 63.0× | (51.83%) |
| FY2022 | 131× | 229.86% |
| FY2021 | 39.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −0.2× | — |
| Sep 2025 | −19.3× | — |
| Dec 2022 | 131× | 87.31% |
| Sep 2022 | 69.8× | — |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BMEA Biomea Fusion, Inc. compare | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| ATNM Actinium Pharmaceuticals, Inc. | 0.2× |
| SGMOQ Sangamo Therapeutics, Inc. compare | 1.2× |
| HYPD Hyperion DeFi, Inc. compare | 24.6× |
| SER Serina Therapeutics, Inc. compare | 32.5× |
| GANX Gain Therapeutics, Inc. compare | 154× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)